ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1369-1375

  Kiselyov, Alexander S ^a   Piatnitski, Evgueni L ^b   Samet, Alexander V ^b   Kisliy, Victor P ^b   Semenov, Victor V ^b  

^a CHEMDIV INC   (United States)

^b N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Angiogenesis; Dual kinase inhibitors; KDR; Receptor tyrosine kinase; Vascular endothelial growth factor receptor; VEGFR 1; VEGFR 2

Indexed keywords

PYRROLE DERIVATIVE; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ARTICLE; CELL ASSAY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PENETRATION; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MONOLAYER CULTURE; SUBSTITUTION REACTION;

ADENOSINE TRIPHOSPHATE; AZOLES; BINDING, COMPETITIVE; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; INHIBITORY CONCENTRATION 50; INTESTINAL ABSORPTION; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33846914231     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.087     Document Type: Article

References (33)

1. Risau W. Nature 386 (1997) 671
2. Hanahan D., and Folkman J. Cell 86 (1996) 353
3. Folkman J., and Klagsburn M. Science 235 (1987) 442
4. Folkman J. J. Natl. Cancer Inst. 82 (1991) 4
5. Kerbel E.S. Carcinogenesis 21 (2000) 505
6. Ferrara N., Gerber H.-P., and LeCouter J. Nat. Med. 9 (2003) 669
7. Carmeliet P., and Jain R. Nat. Med. 9 (2003) 653
8. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Cancer Res. 60 (2000) 203
9. Klagsbrun M., and D'Amore P. Annual Rev. Physiol. 53 (1991) 217
10. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. FASEB J. 13 (1999) 9
11. Zachary I. Biochem. Soc. Trans. 31 (2003) 1171
12. Klagsbrun M., and Moses M.A. Chem. Biol. 6 (1999) R217
13. The anti-angiogenic antibody Avastin™ (Bevacizumab) has recently been approved to treat colorectal cancer, see:. Culy C. Drugs Today 41 (2005) 23
14. The anti-angiogenic aptamer Macugen™ (Pegaptanib sodium) has recently been approved to treat neovascular age-related macular degeneration, see:. Fine S.L., Martin D.F., and Kirkpatrick P. Nat. Rev. Drug Disc. 4 (2005) 187
15. Bold G., Altmann K.-H., Jorg F., Lang M., Manley P.W., Traxler P., Wietfeld B., Bruggen J., Buchdunger E., Cozens R., Ferrari S., Pascal F., Hofmann F., Martiny-Baron G., Mestan J., Rosel J., Sills M., Stover D., Acemoglu F., Boss E., Emmenegger R., Lasser L., Masso E., Roth R., Schlachter C., Vetterli W., Wyss D., and Wood J.M. J. Med. Chem. 43 (2000) 2310
16. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
17. Wedge S.R., Kendrew J., Hennequin L.F., Valentine P.J., Barry S.T., Brave S.R., Smith N.R., James N.H., Dukes M., Curwen J.O., Chester R., Jackson J.A., Boffey S.J., Kilburn L.L., Barnett S., Richmond G.H.P., Wadsworth P.F., Walker M., Bigley A.L., Taylor S.T., Cooper L., Beck S., Juergensmeier J.M., and Ogilvie D.J. Cancer Res. 65 (2005) 4389
18. Manley P.W., Furet P., Bold G., Brüggen J., Mestan J., Meyer T., Schnell C., and Wood J. J. Med. Chem. 45 (2002) 5697
19. Manley P.W., Bold G., Fendrich G., Furet P., Mestan J., Meyer T., Meyhack B., Strauss A., and Wood J. Cell. Mol. Biol. Lett. 8 (2003) 532
20. Altmann, K.-H.; Bold, G.; Furet, P.; Manley, P.W.; Wood, J.M.; Ferrari, S.; Hofmann, F.; Mestan, J.; Huth, A.; Krüger, M.; Seidelmann, D.; Menrad, A.; Haberey, M.; Thierauch, K.-H., US Patent 6,878,720 B2, 2005.
21. Piatnitski E.L., Duncton M., Katoch-Rouse R., Sherman D., Kiselyov A.S., Milligan D., Balagtas C., Wong W., Kawakami J., and Doody J. Bioorg. Med. Chem. Lett. 15 (2005) 4696
22. Kiselyov A.S., Piatnitski E.L., Semenova M., and Semenov V.V. Bioorg. Med. Chem. Lett. 16 (2006) 602
23. Kiselyov A.S., Semenova M., Semenov V.V., Piatnitski E.L., and Ouyang S. Bioorg. Med. Chem. Lett. 16 (2006) 2559
24. Kiselyov A.S., Semenova M., Semenov V.V., and Piatnitski E.L. Bioorg. Med. Chem. Lett. 16 (2006) 1726
25. Kiselyov A.S., Semenova M., Semenov V.V., and Milligan D. Bioorg. Med. Chem. Lett. 16 (2006) 1913
26. Sobenina L.N., Drichkov V.N., Mikhaleva A.I., Petrova O.V., Ushakov I.A., and Trofimov B.A. Tetrahedron 61 (2005) 4841
27. 2: C, 57.45; H, 4.02; N, 14.89; found: C, 57.27; H, 3.85; N, 14.76.
28. McTigue M.A., Wickersham J.A., Pinko C., Showalter R.E., Parast C.V., Tempczyk-Russell A., Gehring M.R., Mroczkowski B., Kan C.C., Villafranca J.E., and Appelt K. Structure 7 (1999) 319
29. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The Protein Data Bank, Nucleic Acids Res. 28 (2000) 235
30. Hanahan D., and Folkman J. Cell 86 (1996) 353
31. Folkman J., and Klagsburn M. Science 235 (1987) 442
32. Zachary I. Biochem. Soc. Trans. 31 (2003) 1171
33. Eskens F. Br. J. Cancer 90 (2004) 1